ArticleVeterinary research2026
The c-di-AMP binding protein NadD from Mesomycoplasma ovipneumoniae functions as a phosphodiesterase that inhibits host inflammatory responses.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cyclic dimeric adenosine monophosphate (c-di-AMP) is a second messenger commonly found in bacteria, particularly within the Firmicutes and Actinobacteria phyla, as well as in Archaea. Phosphodiesterase (PDE) is an enzyme that plays a crucial role in regulating the homeostasis of bacterial c-di-AMP and is capable of hydrolysing this molecule both intracellularly and extracellularly. This enzymatic activity influences various physiological functions in bacteria, modulates the host immune response, and impacts the pathogenic processes of infectious agents. Mesomycoplasma ovipneumoniae (M. ovipneumoniae) is the primary pathogen responsible for mycoplasma pneumonia in sheep, but its pathogenic mechanisms remain poorly understood. This study aimed to investigate the potential role of c-di-AMP and its binding proteins in M. ovipneumoniae in affecting host immune responses. Our findings confirmed that M. ovipneumoniae produced c-di-AMP in both the intracellular extracts and culture supernatants and that it generated c-di-AMP during the infection of sheep primary alveolar macrophages. Transcriptome analysis revealed that c-di-AMP can activate the immune response in macrophages. Furthermore, we identified and characterized the c-di-AMP binding protein nicotinate-nucleotide adenylyltransferase (NadD), which represents a novel class of PDE containing His-Asp (HD) domains in Mycoplasmas. Notably, our study demonstrated that NadD suppresses inflammatory responses in host cells infected with M. ovipneumoniae. In conclusion, this study provides new insights into the pathogenic mechanisms of M. ovipneumoniae and develops potential targets for the prevention and control of ovine mycoplasma pneumonia, as well as for the development of therapeutic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.